Name

Abecma

Alternate Names

Idecabtagene vicleucel
Anti-BCMA CAR T Cells BB2121

Abbreviations

None

Category

Biologic therapy (BRM, immunotherapy)

Subcategory

CAR-T

NSC Number

None

Primary Site

None

Histology

Multiple myeloma

Remarks

March 26, 2021: FDA approved idecabtagene vicleucel (Abecma) for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. This is the first FDA-approved cell-based gene therapy for multiple myeloma.

Coding

This drug should be coded
Glossary